Department of Internal Medicine, Universal College of Medical Sciences, Bhairahawa, Nepal.
Karuna Hospital. Kathmandu, Nepal.
JNMA J Nepal Med Assoc. 2021 Mar 31;59(235):243-247. doi: 10.31729/jnma.6284.
D-dimer is currently the best available marker for COVID-19 associated hemostatic abnormalities. This study aims to find out the prevelance of elevated D-dimer levels in confirmed COVID-19 cases in intensive care unit of a tertiary care hospital of western Nepal.
This descriptive cross-sectional study was conducted among 95 patients admitted to COVID Intensive Care Unit of a teriary care centre from August 2020 to January 2021 after taking ethical clearence from Institutional Review Committee in order to determine the D-dimer levels in confirmed COVID-19 cases. D-dimer value was measured at the admission and the highest D-dimer value was recorded during the course of hospital stay with the risk of mortality in confirmed COVID-19 cases. The normal range of D-dimer was taken as <0.35 mg/dl as per our hospital laboratory standards. Convenience sampling method was used. Data entry and descriptive analysis were done in Statistical Package for the Social Sciences version 25.0, point estimate at 95% Confidence Interval was calculated along with frequency and proportion for binary data.
Out of total 95 cases of COVID-19 included in this study, 25 (89.3%) patients with age ≥ 65 years and 42 (62.69%) patients aged <65 years had elevated D-dimer on admission. Data showed that 29 (67.4%) patients having elevated D-dimer at admission had mortality.
Elevated D-dimer levels was frequently seen in patients admitted in Intensive Care Unit with COVID-19. Our study suggested that measurement of D-dimer may guide in clinical decision making.
D-二聚体是目前 COVID-19 相关止血异常的最佳标志物。本研究旨在了解尼泊尔西部一家三级护理医院重症监护病房中确诊 COVID-19 病例中升高的 D-二聚体水平的患病率。
本描述性横断面研究于 2020 年 8 月至 2021 年 1 月在一家三级护理中心的 COVID 重症监护病房中进行,共纳入 95 例患者,在获得机构审查委员会的伦理许可后,以确定确诊 COVID-19 病例中的 D-二聚体水平。在入院时测量 D-二聚体值,并记录住院期间的最高 D-二聚体值,同时评估确诊 COVID-19 病例的死亡风险。根据我们医院的实验室标准,将 D-二聚体的正常范围定义为<0.35mg/dl。采用便利抽样法。数据录入和描述性分析在社会科学统计软件包 25.0 中进行,计算了 95%置信区间的点估计值,以及二进制数据的频率和比例。
在本研究纳入的 95 例 COVID-19 病例中,25 例(89.3%)年龄≥65 岁和 42 例(62.69%)年龄<65 岁的患者入院时 D-二聚体升高。数据显示,29 例(67.4%)入院时 D-二聚体升高的患者死亡。
COVID-19 患者入住重症监护病房时,D-二聚体水平升高较为常见。我们的研究表明,D-二聚体的测量可能有助于临床决策。